Aspirin Dosing for Cardiovascular Disease

Introduction to Aspirin Therapy

The American Heart Association recommends low-dose aspirin (75-100 mg daily) for all maintenance therapy in cardiovascular disease, while high-dose aspirin (162-325 mg) is reserved only as an initial loading dose in acute coronary syndromes, followed immediately by transition to low-dose maintenance therapy 1, 2

For patients presenting with ACS, administer a loading dose of 162-325 mg of non-enteric coated aspirin, followed immediately by daily low-dose aspirin (75-100 mg) for maintenance therapy 1, 2
The loading dose should be given as soon as possible on presentation, regardless of whether the patient is already taking aspirin 1
Continued use of full-dose aspirin (300-325 mg daily) for 30 days after ACS was not superior to low-dose aspirin (75-100 mg daily) for reducing major adverse cardiovascular events (MACE) but was associated with increased minor and gastrointestinal bleeding 1, 2
Non-enteric coated formulations are essential during the acute phase to ensure rapid absorption 3

For all patients with established atherosclerotic cardiovascular disease, use low-dose aspirin 75-162 mg daily indefinitely 4, 5
The 75-100 mg daily dose exceeds the minimal effective dose required for complete platelet thromboxane A2 suppression while allowing for interindividual variability in drug response 1, 2
When used with ticagrelor as dual antiplatelet therapy, aspirin should be limited to 81 mg daily (not higher doses) 2, 3
Low-dose aspirin (75 mg daily) may be equally or more effective than higher doses (500-1,500 mg daily), with risk reductions of 29.7% versus 21.4% respectively in cardiovascular events 5, 6

For primary prevention in adults 40-70 years at higher ASCVD risk but not at increased bleeding risk, low-dose aspirin (75-100 mg daily) might be considered, though benefits are modest and must be weighed against bleeding risk 7
Aspirin should NOT be routinely administered for primary prevention in adults >70 years of age due to increased bleeding risk that outweighs benefits 7
For patients with diabetes and elevated cardiovascular risk, low-dose aspirin (75-162 mg daily) may be considered for primary prevention 4, 8
Aspirin is contraindicated in patients <21 years due to Reye syndrome risk 5, 6, 8

High-dose aspirin (≥160 mg daily) is associated with increased bleeding risk without improved cardiovascular outcomes compared to low-dose therapy 3
The most common low-dose tablet in the U.S. is 81 mg, which provides optimal efficacy with minimal side effects 8

Never use enteric-coated aspirin for acute coronary syndromes as it has delayed and reduced absorption that compromises immediate antiplatelet effects 3
Do not continue high-dose aspirin beyond the initial loading dose in ACS patients, as this increases bleeding without improving outcomes 1, 2
Avoid combining aspirin with NSAIDs as this significantly increases GI ulceration and bleeding risk without additional cardiovascular benefit 1, 2